After the historic approval of the company’s first-ever drug in January 2021, Aurinia Pharmaceuticals announced the acquisition of two pipeline assets that align with the Canadian biotech’s focus on autoimmune and kidney-related disease.
Bharat Biotech’s a two-dose, injectable Covid-19 vaccine Covaxin is authorized in India for ages 12 and up. The company is moving forward with a second vaccine against the novel coronavirus with a different mode of administration.
The Feinstein Institutes for Medical Research, the research unit of New York State health care provider Northwell Health, may have found a way to control neurons that drive inflammation.
Pfizer Inc. and the company’s German partner BioNTech SE submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their Covid-19 vaccine, the drugmakers said on Aug. 16.
Eli Lilly announced the success of the global health care company’s clinical trial on lebrikizumab as a treatment for people diagnosed with moderate to severe atopic dermatitis (AD).
Two experimental cancer drugs, one for ovarian cancer and one for a form of breast cancer, received Fast Track designation from the U.S. Food and Drug Administration, which will speed up the regulatory process for these medications.
Although the endocannabinoid system has been intensely studied, there are still few drugs approved or in development that interact with it.
Lomecel-B – Longeveron’s proprietary off-the-shelf cell therapy for aging frailty – failed the six-minute walk test (6MWT) endpoint of a Phase IIb study, according to a statement published by the Miami-based biotech on Aug. 13.
An antiviral treatment under development by Atea Pharmaceuticals is showing promise against Covid-19.
A study in Science shed new light on the global epidemic obesity by evaluating nearly 650,000 exomes from the United Kingdom, United States and Mexico and identifying those with strong implications for body mass or obesity.
